A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Running, not enrolling · Phase 1/Phase 2

Conditions studied: NSCLC, Melanoma

In brief

The objective of this study is to assess safety and efficacy of BA3071 in solid tumors

Key facts

Study ID

NCT05180799

Run by

BioAtla, Inc.

People needed

320

Starts

2022-08-03

Expected to finish

2026-06-30

Last updated by the study team

2025-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have measurable disease.
• Age ≥ 18 years
• CLTA-4 blocking-antibody naïve
• Adequate renal function
• Adequate liver function
• Adequate hematological function
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Patients must have single or any combination of the following mutations: KRAS, STK11, KEAP1 and/or PD-L1 TPS <1%
• Patients must be eligible for surgery (NSCLC Stage IIB-IIIA only)

You may not qualify if…

• Patients must not have clinically significant cardiac disease.
• Patients must not have known non-controlled CNS metastasis.
• Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
• Patients must not have had major surgery within 4 weeks before first BA3071 administration.
• Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
• Patients must not be women who are pregnant or breast feeding.

Where it is running

• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Piedmont West — Atlanta, Georgia, United States
• Northwest Cancer Centers — Dyer, Indiana, United States
• Morristown Medical Center/Atlantic Health System — Morristown, New Jersey, United States
• Icahn School of Medicine at Mt. Sinai — New York, New York, United States
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
• Providence Cancer Institute — Portland, Oregon, United States
• University of Utah Huntsman Cancer Institute — Salt Lake City, Utah, United States
• Border Medical Oncology Research Unit at Albury Wodonga Regional Cancer Centre — Albury, New South Wales, Australia
• Cancer Care Foundation — Miranda, New South Wales, Australia
• Cancer Research South Australia — Adelaide, South Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.